The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold?

This is a generated summary. It shows the 5 most-liked posts from a topic of 24, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
AR
a.reyesTL4 Admin6 Nov 2024#1

TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked.

Comparing STEP 8 (JAMA, 2022) with SCALE (N Engl J Med, 2015) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

38 likes 21mo
FR
f.rasmussenTL2 Moderator21 Nov 2024#6

Worth separating two things that post #2 runs together.

BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.

29 likes 20mo
CH
ca.haddadTL2 Moderator11 Dec 2024#16
priorauth_notes, post #7: What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here. Go to post

This follows post #13 rather than contradicting it.

Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.

26 likes in reply to #7 20mo
SC
s.cardosoTL2 Moderator18 Dec 2024#20

Picking up post #17: that is the part I would want checked first.

The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.

19 likes 19mo
PW
PharmNotes_WhitfieldTL4Pharmacist25 Dec 2024#24

On post #20 — agreed on the reasoning, with one qualification.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

26 likes 19mo

Read the full topic (24 posts)

This topic was closed 60 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

TopicParticipantsRepliesViewsActivity
What would change my mind about repair peptides: a specific answer — one year on
What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: STEP 1 ( N Engl J Med…
CTLLFVON+9 13 42k 19mo
Why the absence of controlled human data on BPC-157 matters more than people admit
Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022) with…
CMVMPFNBHF+60 66 16k 1d
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet ,…
FAKLSLAS+50 55 7.8k 2d
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold?
The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen…
ASBSMCSBLS+6 10 3.1k 1d
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset
On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019)…
WNCDSOOSB+77 84 54k 11mo

Related topics — sharing the tags TB-500, BPC-157, needs a source

TopicParticipantsRepliesViewsActivity
Sequence verification for an obscure compound: how it is done
Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with SURMOUNT-1 ( N…
BNGVIAJVGE+104 114 10k 12mo
CJC-1295 with and without DAC: what the modification does
On the subject in the title: CJC-1295 with and without DAC: what the modification does Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with SURMOUNT-OSA ( N Engl J Med ,…
MSNCDHEHNE+117 123 5.6k 22h
A preprint whose numbers changed substantially at publication
A preprint whose numbers changed substantially at publication — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read it before posting;…
IBCNNDBRC+90 95 21k 9mo
A widely repeated interaction claim that turns out to be unsupported
On the subject in the title: A widely repeated interaction claim that turns out to be unsupported Working notes rather than a conclusion. Practical question with the units stated, because I have seen how…
NKRGBNMSDT+47 51 37k 3mo
Delayed gastric emptying and oral medication absorption: which drugs matter — one year on
On the subject in the title: Delayed gastric emptying and oral medication absorption: which drugs matter — one year on Working notes rather than a conclusion. I have read the maintained page on this and I…
MAKSVCD 3 16k 2mo